Skip to main content
Livermore
Livermore
ZHEN

Patient Capital Management, LLC

SEC CIK
0001854794
Latest filing
Aug 13, 2026

The latest 13F from Patient Capital Management, LLC covers Q2 2026 (filed Aug 13, 2026): 39 long positions worth $3.01B. The top 10 holdings make up 52.1% of the portfolio, and the largest is Royalty Pharma plc (RPRX) at 6.7%. Livermore has 19 filings on Form 13F from this institution, going back to Q4 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
2
Est. +$73.3M
Added
11
Est. +$115.3M
Reduced
24
Est. −$201.7M
Sold out
1
Est. −$42.3M

Top 5 holdings

Share of this quarter's portfolio value

  1. RPRXRoyalty Pharma plc
    6.7%$201.8MHistory
  2. CCitigroup Inc
    6.5%$196.4MHistory
  3. GOOGLAlphabet Inc.
    6.2%$187.9MHistory
  4. UNHUnitedHealth Group Inc
    6.0%$182.0MHistory
  5. AMZNAmazon Com Inc
    5.4%$162.3MHistory

Share of portfolio

Top 5 holdings and the other 34 positions, by share of portfolio value

  1. RPRX6.7%
  2. C6.5%
  3. GOOGL6.2%
  4. UNH6.0%
  5. AMZN5.4%
  6. Other 34 positions69.1%

Biggest buys

New and added positions, by estimated amount bought

  1. GPNGlobal Payments Inc
    +$68.4MNewHistory
  2. FBTCFidelity Wise Origin Bitcoin Fund
    +$44.1MAddedHistory
  3. CHYMChime Financial, Inc.
    +$24.6MAddedHistory
  4. ADBEAdobe Inc.
    +$13.1MAddedHistory
  5. PGENPrecigen, Inc.
    +$6.95MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. GPNGlobal Payments Inc
    +2.27 pp0.0% → 2.3%History
  2. UNHUnitedHealth Group Inc
    +1.64 pp4.4% → 6.0%History
  3. FBTCFidelity Wise Origin Bitcoin Fund
    +1.29 pp0.8% → 2.1%History
  4. PGENPrecigen, Inc.
    +1.03 pp2.6% → 3.6%History
  5. CHYMChime Financial, Inc.
    +0.77 pp2.0% → 2.8%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. NENoble Corp plc
    −$46.5MReducedHistory
  2. IBITiShares Bitcoin Trust ETF
    −$42.3MSold outHistory
  3. ILMNIllumina, Inc.
    −$35.1MReducedHistory
  4. BIIBBiogen Inc.
    −$20.8MReducedHistory
  5. UBSUBS Group AG
    −$14.3MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. NENoble Corp plc
    −2.34 pp2.5% → 0.1%History
  2. IBITiShares Bitcoin Trust ETF
    −1.58 pp1.6% → 0.0%History
  3. SDRLSEADRILL Ltd
    −1.20 pp3.7% → 2.5%History
  4. BIIBBiogen Inc.
    −0.56 pp2.6% → 2.0%History
  5. ETEnergy Transfer LP
    −0.52 pp4.4% → 3.9%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$3.01B
+$327.7M (+12.2%) vs. prior quarter
Positions
39
+1 vs. prior quarter
Top 10 concentration
52.1%
Top 10 as share of value
Turnover
6.6%
Q2 2026, one quarter
Average holding period
13.1 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2021), so positions held before then are understated.

13F filings by quarter

19 quarters, going back to Q4 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $3.01B (Q2 2026)

Q4 2021: $246.9MQ1 2022: $254.3MQ2 2022: $205.2MQ3 2022: $197.1MQ4 2022: $204.1MQ1 2023: $224.5MQ2 2023: $1.80BQ3 2023: $1.70BQ4 2023: $1.89BQ1 2024: $2.05BQ2 2024: $1.88BQ3 2024: $2.04BQ4 2024: $2.17BQ1 2025: $1.94BQ2 2025: $2.22BQ3 2025: $2.50BQ4 2025: $2.59BQ1 2026: $2.68BQ2 2026: $3.01B
Q4 2021Q2 2026
13F filings of Patient Capital Management, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 13, 202639$3.01BRPRXCGOOGLvs. Q1 2026SEC
Q1 2026May 14, 202638$2.68BRPRXCGOOGLvs. Q4 2025SEC
Q4 2025Feb 13, 202640$2.59BGOOGLCAMZNvs. Q3 2025SEC
Q3 2025Oct 30, 202541$2.50BGOOGLCUNHvs. Q2 2025SEC
Q2 2025Aug 13, 202540$2.22BQXOAMZNCvs. Q1 2025SEC
Q1 2025May 14, 202539$1.94BAMZNCQXOvs. Q4 2024SEC
Q4 2024Feb 14, 202543$2.17BAMZNQXOGOOGLvs. Q3 2024SEC
Q3 2024Nov 14, 202441$2.04BQXOAMZNGOOGLvs. Q2 2024SEC
Q2 2024Aug 14, 202440$1.88BAMZNGOOGLCvs. Q1 2024SEC
Q1 2024May 15, 202442$2.05BAMZNCEXPEvs. Q4 2023SEC
Q4 2023Feb 14, 202443$1.89BEXPEAMZNOMFvs. Q3 2023SEC
Q3 2023Nov 14, 202342$1.70BEXPEAMZNOMFvs. Q2 2023SEC
Q2 2023Aug 14, 202344$1.80BAMZNEXPEOMFvs. Q1 2023SEC
Q1 2023May 15, 202342$224.5MEXPEOMFETvs. Q4 2022SEC
Q4 2022Feb 14, 202342$204.1MOVVEXPEOMFvs. Q3 2022SEC
Q3 2022Nov 14, 202241$197.1MOVVEXPETEVAvs. Q2 2022SEC
Q2 2022Aug 15, 202240$205.2MBABAOVVMATvs. Q1 2022SEC
Q1 2022May 16, 202242$254.3MOVVAMZNBABAvs. Q4 2021SEC
Q4 2021Feb 14, 202238$246.9MGOOGLMETANCLH–SEC

13D and 13G filings

Companies where Patient Capital Management, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

1 company, largest stake first.

Companies where Patient Capital Management, LLC owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
PGENPrecigen, Inc.13G/A10.20%36.0M shares−3.40 ppfrom 13.60%Feb 14, 20245 filingsFeb 13, 2026SEC

Latest filings

14 filings on file made by Patient Capital Management, LLC or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Patient Capital Management, LLC
CompanyFiled (ET)FormStakeChangeEvent dateFiling
PLAYDave & Buster's Entertainment, Inc.May 8, 20261:21 PM ET13G/A3.32%1.15M shares−2.40 ppfrom 5.72%Below 5%Mar 31, 2026SEC
S4 Capital plcCommon StockFeb 13, 202610:57 AM ET13G/A4.69%31.4M shares−1.42 ppfrom 6.11%Below 5%Dec 31, 2025SEC
PGENPrecigen, Inc.Feb 13, 202610:56 AM ET13G/A10.20%36.0M shares−3.40 ppfrom 13.60%Dec 31, 2025SEC
PGENPrecigen, Inc.Oct 30, 202512:49 PM ET13G/A13.60%45.2M shares+7.07 ppfrom 6.53%Dec 31, 2024SEC
GOOSCanada Goose Holdings Inc.Aug 14, 20254:01 PM ET13G/A1.60%735.2K shares−4.23 ppfrom 5.83%Below 5%Jun 30, 2025SEC
PLAYDave & Buster's Entertainment, Inc.Apr 30, 20255:02 PM ET13G5.72%2.20M sharesNewMar 31, 2025SEC
GOOSCanada Goose Holdings Inc.Apr 24, 20255:26 PM ET13G/A5.83%0 shares−2.59 ppfrom 8.42%Mar 31, 2025SEC
GOOSCanada Goose Holdings Inc.Feb 12, 20252:55 PM ET13G/A8.42%3.81M shares–Dec 31, 2024SEC
S4 Capital plcCommon StockFeb 12, 202510:52 AM ET13G/A6.11%39.7M shares–Dec 31, 2024SEC
PGENPrecigen, Inc.Feb 12, 202510:51 AM ET13G/A6.53%17.7M shares–Dec 31, 2024SEC
PGENPrecigen, Inc.Feb 27, 202413G/AOld format–––SEC
S4 Capital plcFeb 14, 202413GOld format–New–SEC
PGENPrecigen, Inc.Feb 14, 202413GOld format–New–SEC
GOOSCanada Goose Holdings Inc.Feb 14, 202413GOld format–New–SEC